Conference Home

Scientific Agenda

Venue Location

Sponsorship


Best of Oncology East 2017

The Best of Oncology East 2017 Conference is organized by OncologyEducation and the Community Oncologists of Metropolitan Toronto (COMET). This meeting will highlight the top 3-4 most clinically relevant achievements of 2017 for nine different tumour sites, and the faculty will be drawn from some of the most influential oncologists across the globe. This event will be co-chaired by Dr. Scott Berry, Dr. Dorothy Lo and Dr. Robert El-Maraghi.

Learning Objectives:

 • To discuss the pivotal oncology trials presented in the different disease sites

 • To review the current standard of care for key malignancies

 • To discuss the current controversies in the management of specific cancers 


FEES

Early Bird Price
(Ending October 23, 2017):
Physicians: $129 CAD
Nurses/Pharmacists/Residents/Students/Allied Healthcare Providers: $65 CAD

Regular Price
(After October 23, 2017):
Physicians: $179 CAD
Nurses/Pharmacists/Residents/Students/Allied Healthcare Providers: $95 CAD


ABOUT THE CHAIRS

Dr. Scott Berry, BSc, MD, MHSc, FRCPC, is a medical oncologist at Sunnybrook Odette Cancer Centre and an Associate Professor in the Faculty of Medicine at the University of Toronto. He completed his general medical training and medical oncology training at the University of Toronto. Dr. Berry is an active participant in clinical research at the National Cancer Institute of Canada (NCIC) Clinical Trials Group and the North American Intergroup. He has been involved in important international trials in colorectal cancer that have been published in journals including the New England Journal of Medicine and the Annals of Oncology. Dr. Berry has also authored several prostate and colorectal cancer guidelines for the Cancer Care Ontario Program in Evidence Based Care and chaired national consensus guideline meetings for the Colorectal Cancer Association of Canada.

Dr. Berry also loves teaching and holds several leadership positions in education. He has won several teaching awards including the University of Toronto Division of Medical Oncology Education Award. He chairs the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology. He is the Program Director for the Medical Oncology Training Program at the University of Toronto and Co-Medical Director of www.OncologyEducation.com.

His other academic interests are the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry holds a master's degree in bioethics from the University of Toronto. He has also served on the ASCO Ethics Committee and is the ethics advisor to the pan-Canadian Oncology Drug Review and the NCIC Data Safety Monitoring Committee.

 

Dr. Dorothy Lo, MD, MHA, is a staff oncologist at St. Joseph’s Health Centre in Toronto.

She completed her oncology residency at the University of Toronto in 2007. Dr. Lo also holds a Masters of Health Administration from the University of Toronto.

Dr. Lo contributes to the medical community by serving as the Secretary for the Hematology/Oncology Section of the Ontario Medical Association. She has been the Co-Chair of education for the Community Oncologists of Metropolitan Toronto (COMET) since 2008.

 

 

Dr. Robert El-Maraghi, BSc., MD, FRCPC, is a medical oncologist at the Simcoe Muskoka Regional Cancer Centre where he specializes in the management of thoracic and gastrointestinal malignancies.

He is the current Chief of Oncology at the Simcoe Muskoka Regional Cancer Centre, a director of the Community Oncologists of Metropolitan Toronto (COMET), a collaborative group of community Medical Oncologists and Hematologists in Ontario and also acts as Co-Chair of the COMET Education Committee and the Georgian Bay Oncology Group. He is also Co-Chair of the annual Canadian Conference of Community Oncology (CCOCO) meeting. He is an examiner for the Medical Council of Canada and holds an appointment of Clinical Lecturer at the University of Toronto.

 


Please contact Lucas Severin, Event Coordinator, at lucas@oncologyeducation.com with any inquiries.

Oncology Clinical News

Bristol-Myers Kidney Cancer Drug Fails Late-stage Trial

(Reuters) Aug 15, 2017 - Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.
Read full article.

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma

(Yahoo! Finance) Aug 16, 2017 - Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Read full article.

Powered by OBR Oncology